Efficacy of induction regimens for cryptococcal meningitis in HIV-infected adults: a systematic review and network meta-analysis

Chang-Hua Chen1,2,3,4, Hua Li5,14, Hsien-Meng Chen3, Yu-Min Chen6, Yu-Jun Chang7, Pao-Yen Lin8,9, Chih-Wei Hsu8,10, Ping-Tao Tseng11, Kai-Huang Lin12 & Yu-Kang Tu5,13

Cryptococcal meningitis (CM) is the most fatal adult meningitis in patients with human immunodeficiency virus (HIV). There is no conclusive evidence for the superiority of 1-week amphotericin B deoxycholate (AmphB) + flucytosine (5-FC) regimen over other antifungals in the management of HIV patients with CM (HIV–CM patients). We aimed to evaluate the differences in efficacy and tolerability of different antifungal agents in HIV–CM patients by conducting a current network meta-analysis (NMA). Overall, 19 randomized controlled trials were included with 2642 participants. A regimen indicated a possibly lower early mortality rate, namely, AmphB + 5-FC + Azole (OR = 1.1E−12, 95% CIs = 1.3E−41 to 0.06) comparing to AmphB + 5-FC. The current NMA provides evidence that AmphB + 5-FC + Azole are superior to all the investigated treatments for induction regimen in HIV–CM patients.

Cryptococcal meningitis (CM) is the most fatal meningitis in adult patients with human immunodeficiency virus (HIV)1–3 infection, particularly in those with acquired immunodeficiency syndrome4. An effective anti-cryptococcal regimen is needed to treat HIV-associated CM (HIV–CM)5,6. HIV–CM treatment can be divided into three phases: induction, consolidation, and maintenance5,7. During the induction phase, antifungal treatment needs to decrease cryptococcal burden in the cerebrospinal fluid (CSF) to increase patient survival5,8. Amphotericin B deoxycholate (AmphB)-based regimen is widely used during the 2-week induction period for HIV–CM, with fluconazole or flucytosine (5-FC) being used for synergistic effects5,9. Research suggests that fluconazole has good tissue penetration10; moreover, 5-FC has a fungicidal effect against Cryptococcus neoformans5. The updated WHO (2018) guidelines for the preferred induction regimens to treat HIV–CM6 recommended a change from 2 weeks of AmphB + 5-FC or 2 weeks AmphB + fluconazole into 1 week of AmphB + 5-FC followed by 1 week of fluconazole, and this offers a lower risk of medication toxicity and a reduced risk of nosocomial sepsis6,11.

The WHO recommendation was based largely on the findings of meta-analyses reporting that 1 week of AmphB + 5-FC was possibly superior to other regimens6,11,12. However, the amount of outcome data used in these analysis was insufficient for direct comparisons between regimens, resulting in an imprecise evaluation of treatment effects12. A new study of a novel single-dose 10 mg/kg liposomal AmphB (LipAmphB) showed no statistically significant compared to 14 days of 3 mg/kg/day LipAmphB13; furthermore, additional information on this topic has now become available14. A network meta-analysis (NMA) showed similar efficacy between the 1-week and 2-week induction regimens of AmphB + 5-FC12. In addition, 5-FC is both non-accessible and
non-affordable in resource-limited settings that experience heavy cryptococcal burden, such as Africa. Another
NMA that compared the efficacy of AmphB + 5-FC and AmphB + fluconazole showed similar outcomes of late
mortality rate. These reports demonstrated that the most effective and tolerable induction regimen for HIV–CM
has not been completely elucidated as yet. Therefore, we conducted a systematic review and NMA of randomized
controlled trials (RCTs) to compare the efficacy and safety of induction regimens of anti-cryptococcal agents
in HIV–CM patients.

Materials and methods
A systematic review and NMA were performed to evaluate the effectiveness and safety of different induction
regimens in HIV patients with CM (HIV–CM patients). This protocol was approved by the institutional review
board of Changhua Christian Hospital (CCH IRB No. 180801). The current study compared the efficacy and
safety of induction regimens between AmphB + 5-FC and other available regimens in treating HIV–CM patients
(Supplementary Table 1). The current NMA was performed according to the preferred reporting items for sys-
tematic reviews and meta-analyses (PRISMA) extension guideline for NMAs (Supplementary Table 2, Fig. 1).

Search strategy and selection criteria.
Several electronic databases were searched from their creation
up to Feb 28, 2020: the Cochrane Infectious Diseases Group Trial Register, the Cochrane Central Register of
Controlled Trials, MEDLINE (accessed via PubMed). Keywords and search terms used when looking for clini-
cal trials are listed in Supplementary Table 3; the search was not limited to publications in English. However,
reviews, correspondence, case reports, expert opinions, and editorials were excluded (Supplementary Table 4).

Data collection and inclusion criteria.
Following the PRISMA guideline, two reviewers (CHC, CYM) screened separately the titles and abstracts of identified articles. Discrepancies or issues of study methodology and quality were resolved by consulting with the third reviewer (CYJ). Studies were included if (1) patients were randomly assigned to different treatments; (2) they were published as full-length articles in peer-reviewed journals, and (3) the efficacy or adverse events of antifungals in treating CM were reported. Excluded studies are listed in the Supplementary Table 4.

Data extraction.
An information-extraction form was created and the following data were collected: (1) details of study design and publication; (2) baseline patient information; (3) the total number of recruited patients; (4) all-cause mortality rates by weeks 2 and 10; (5) mycological suppression; (6) hepatic adverse reaction (Supplementary Tables 5 and 6).

Outcome definitions.
Two primary outcomes and two secondary outcomes were identified. Two primary outcomes were early mortality rate and late mortality rate. The definition of early mortality rate was all-cause mortality rate within 2 weeks of diagnosing CM. The definition of late mortality rate was all-cause mortality rate.
occurring more than 6 weeks after diagnosing CM. Two secondary outcomes were microbiological eradication and hepatic adverse reaction. The microbiological-eradication outcome was derived from measuring mycological suppression based on quantitative CSF cultures or the rate of change in colony-forming-units (CFU) of fungal cultures during the initial 2 weeks of induction. The mycological suppression improvement was defined as the mycological suppression decline at a rate of ≤0.33 log CFU/day or the equal effect during the first 14 days of treatment.17 The adverse reaction data were derived from the reported rate of liver damage events. The short course of AmphB was defined as being of 1-week duration. The azole regimen was defined as fluconazole and voriconazole in current study. The high dose of azole (azole_H) was defined as fluconazole being larger than 800 mg/day. Characteristics of the early- and late-mortality rates of the included studies are listed in the Supplementary Table 5. Characteristics of the microbiological eradication and hepatic adverse reactions in the included studies are shown in the Supplementary Table 6. Supplementary Table 7 details the key findings of the included studies.

Cochrane risk-of-bias tool and GRADE ratings. Two independent reviewers (CHC, CYM) evaluated the risk of bias for each domain described in the Cochrane risk-of-bias tool.18 The study evaluated the certainty of the evidence according to the GRADE framework.19

Network meta-analysis. The odds ratio (OR) with 95% confidence interval (CI) was summarized as the effect size for measuring all outcomes. We undertook the frequentist approach to NMA by using the mvmeta command, written for the statistical software package Stata (version 16.0, StataCorp LLC, Texas 77845 USA). When the numbers of event were small, we adopted the Bayesian approach by using the software package WinBUGS (version 1.4.3, Medical Research Council Biostatistics Unit, Cambridge, Massachusetts) and R version 3.6.1 (http://www.r-project.org/). Because the pooled estimates of these pairs are different, funnel plots for NMA center the effect size of each pair of treatments. And, we centered the effect sizes according to previous methodology.20 We evaluated the potential inconsistency between direct and indirect evidence by using the deign-by-treatment interaction model, loop inconsistency model and node-splitting model.21,22 We also computed the ranking probabilities of treatments which were then summarized by the surface under the cumulative ranking area (SUCRA) ranging from 0 to 1. A treatment with a greater SUCRA value indicates that its efficacy is closer to that of a perfect treatment which is always the best and has a SUCRA value of 1.

Ethical approval. The study was approved by the institutional review board of Changhua Christian Hospital (CCH IRB No. 180801).

Results

Characteristics and description of the included studies. In total, 46 publications were considered for full-text review, and 27 were excluded (Supplementary Table 3). Finally, 19 articles were included in our NMA (Supplementary Table 5). The quality of the included studies and their risk of bias were rated. Figure 1 depicts the entire geometric distribution of the treatment arms. A total of 2642 participants were included; the baseline characteristics of the included participants are summarized in Supplementary Tables 4 and 5. In brief, 19 studies reported the early-mortality rate and 5 were multi-arm trials; 18 reported the late-mortality rate and 5 were multi-arm trials; 10 reported mycological suppression and 4 were multi-arm trials; and 11 reported hepatic adverse reaction involving 3 multi-arm trials. Figure 2 and Supplementary Figure 1 depict the entire geometric distribution of the treatment arms for four different outcomes.

Primary outcomes. The NMA showed that all the investigated antifungals associated with early mortality rate were similar to those seen in the AmphB + 5-FC-treated participants with CM (Fig. 3a). According to the forest plot, three regimens were possibly related to lower early mortality rate, namely AmphB + 5-FC + Azole (OR = 1.1E−12, 95% CIs = 1.3E−41 to 0.06), liposomal amphotericin B (LipAmphB) (OR = 1.1E−8, 95% CIs = 1.4E−36 to 4.0E−11), and LipAmphB + Azole (OR = 3.6E−8, 95% CIs = 3.0E−36 to 1.12E+12) comparing to AmphB + 5-FC. According to the league table (Supplementary Table 8A), and the SUCRA evaluation (Supplementary Table 8B), Azole_H alone presented the highest early mortality rate and 5-FC + AmphB_S (OR = 0.89, 95% CIs = 0.13–6.3), and LipAmphB (OR = 0.96, 95% CIs = 0.11–6.1) compared to AmphB + 5-FC. In contrast, two regimens were possibly related to lower early mortality rate, namely AmphB + 5-FC + Azole_H (Supplementary Table 9), and Azole_H was associated with the lowest risk of early mortality rate followed by AmphB_S + 5-FC + azole_H.

Co-primary outcome: late mortality rate. The NMA revealed that all the investigated antifungals associated with the late-mortality rate were similar to the AmphB + 5-FC in participants with CM (Fig. 3b). According to the forest plot, the Azole_H was possibly associated with the lowest late-mortality rate (OR = 0.71, 95% CIs = 0.15–4.4), AmphB_S + 5-FC + other (OR = 0.89, 95% CIs = 0.13–6.3), and LipAmphB (OR = 0.96, 95% CIs = 0.11–6.1) compared to AmphB + 5-FC. In contrast, two regimens were possibly related to lower late-mortality rate, namely AmphB + 5-FC + Azole_H (Supplementary Table 9), and Azole_H was associated with the lowest risk of late-mortality rate followed by AmphB_S + 5-FC + azole_H.
a poorly fungicidal activity, namely azole_H (OR = 3.8, 95% CIs = 0.62–23) and azole_H + others (OR = 2.2, 95% CIs = 0.46–14). According to SUCRA (Supplementary Table 9), others + azole_H was associated with the lowest microbiological activity followed by AmphB + 5-FC + others and an AmphB + 5-FC.

Figure 2. Network structure of network meta-analysis of different outcomes for cryptococcal meningitis in HIV patients. (a) Network structure of network meta-analysis of early mortality rate for cryptococcal meningitis in HIV patients. (b) Network structure of network meta-analysis of late mortality rate for cryptococcal meningitis in HIV patients.
The NMA revealed that all the investigated antifungals were associated with a hepatic-adverse-event rate similar to that of AmphB and 5-FC in participants with CM (Supplementary Figure 2B, Supplementary Table 8D). According to the forest plot, the azole regimen was probably associated with the lowest adverse event (OR = 0.075, 95% CIs = < 0.001–1.6) followed by LipAmB (OR = 0.50, 95% CIs = 0.018–11) and azole_H + 5-FC (OR = 0.55, 95% CIs = 0.059–3.9) comparing to AmphB with 5-FC.

**Risk of bias, publication bias, inconsistency assessment, and GRADE ratings.** We found that 61.7%, 14.3%, and 24.0% of the enrolled 19 studies showed a low, unclear, and high risk of bias, respectively.
AmphB + 5-FC-based therapy was superior to other regimens used to treat HIV–CM. As shown in a previous induction regimens in HIV–CM patients. In contrast to Tenforde et al., our study did not found that 1-week due to poor fungicidal activity. In summary, AmphB + 5-FC + Azole are superior to all investigated regimens for with a similar early mortality rate and also with a similar late mortality rate in HIV–CM patients. Based on mycological suppression, the azole_H alone was not recommended to be induction regimen in HIV–CM patients due to poor fungicidal activity. In summary, AmphB + 5-FC + Azole are superior to all investigated regimens for induction and the azole_H alone was not recommended to be induction regimen in HIV–CM patients due to poor fungicidal activity in HIV–CM patients.

Our NMA also found that the AmphB + 5-FC + Azole are superior to all the investigated treatments for induction regimens in HIV–CM patients. In contrast to Tenforde et al., our study did not found that 1-week AmphB + 5-FC-based therapy was superior to other regimens used to treat HIV–CM. As shown in a previous meta-analysis, the combination of AmphB + 5-FC + azole showed mostly significantly lower early mortality rate (Fig. 1), but, the result came from only a single study. The evidence is not conclusive due to the small sample bias. In addition, there was no statistically significant difference in mortality rates and hepatic adverse events between AmphB + azole_H and AmphB + 5-FC for HIV–CM patients. Briefly, our study shows 1-week AmphB + 5-FC remains the best preferred regimen than others in HIV–CM patients.

The goal of treating CM is to attain cryptococcal eradication and to protect from neurological damage. Mycological suppression could achieve fungal eradication in CSF as a prognostic factor. In previous studies, mycological suppression was independently associated with mortality. Our result is similar to a previous report showing no statistically significant difference in MS between the investigated antifungals. Our current NMA revealed that all the investigated antifungals were associated with a similar mycological suppression compared to AmphB + 5-FC in participants with mycological suppression, but the azole_H alone presented with poorly fungicidal activity (OR = 3.8, 95% CIs = 0.62–23). The results of our analysis is in line with those of a previous report that the azole_H alone was not recommended to be an induction regimen in HIV–CM patients due to poor fungicidal activity. Due to disconnection of network from the reporting of mycological suppression events, the secondary outcome needs further evaluation to elucidate this viewpoint.

Anti-fungal agents have high toxicity and cause hepatotoxicity, although the effectiveness of AmphB for HIV–CM patients is outstanding. The administration of azole with AmphB is recommended for the induction treatment of CM. The most frequent hepatic adverse events were due to an increased hepatic injury related to azole. Guidelines issued in 2010 recommended AmphB plus fluconazole (800 mg/day) as the induction therapy. According to the current NMA, azole_H did not achieve a significantly cumulative hepatic toxicity effect. Moreover, AmphB plus fluconazole (800 mg/day) could be adopted as the standard induction antifungal regimen after Cryptococcal Optimal ART Timing Trial for HIV–CM patients.

Discussion
Our NMA summarizes the current evidence on the efficacy and tolerability of the induction therapy for individual antifungals in HIV–CM patients. And our results showed that AmphB + 5-FC + Azole as induction regimen yielded a lower mortality rate than other antifungal regimens. All the investigated antifungals were associated with a similar early mortality rate and also with a similar late mortality rate in HIV–CM patients. Based on mycological suppression, the azole_H alone was not recommended to be induction regimen in HIV–CM patients due to poor fungicidal activity. In summary, AmphB + 5-FC + Azole are superior to all investigated regimens for induction and the azole_H alone was not recommended to be induction regimen in HIV–CM patients due to poor fungicidal activity in HIV–CM patients.

Our NMA also found that the AmphB + 5-FC + Azole are superior to all the investigated treatments for induction regimens in HIV–CM patients. In contrast to Tenforde et al., our study did not found that 1-week AmphB + 5-FC-based therapy was superior to other regimens used to treat HIV–CM. As shown in a previous meta-analysis, the combination of AmphB + 5-FC + azole showed mostly significantly lower early mortality rate (Fig. 1), but, the result came from only a single study. The evidence is not conclusive due to the small sample bias. In addition, there was no statistically significant difference in mortality rates and hepatic adverse events between AmphB + azole_H and AmphB + 5-FC for HIV–CM patients. Briefly, our study shows 1-week AmphB + 5-FC remains the best preferred regimen than others in HIV–CM patients.

The goal of treating CM is to attain cryptococcal eradication and to protect from neurological damage. Mycological suppression could achieve fungal eradication in CSF as a prognostic factor. In previous studies, mycological suppression was independently associated with mortality. Our result is similar to a previous report showing no statistically significant difference in MS between the investigated antifungals. Our current NMA revealed that all the investigated antifungals were associated with a similar mycological suppression compared to AmphB + 5-FC in participants with mycological suppression, but the azole_H alone presented with poorly fungicidal activity (OR = 3.8, 95% CIs = 0.62–23). The results of our analysis is in line with those of a previous report that the azole_H alone was not recommended to be an induction regimen in HIV–CM patients due to poor fungicidal activity. Due to disconnection of network from the reporting of mycological suppression events, the secondary outcome needs further evaluation to elucidate this viewpoint.

Anti-fungal agents have high toxicity and cause hepatotoxicity, although the effectiveness of AmphB for HIV–CM patients is outstanding. The administration of azole with AmphB is recommended for the induction treatment of CM. The most frequent hepatic adverse events were due to an increased hepatic injury related to azole. Guidelines issued in 2010 recommended AmphB plus fluconazole (800 mg/day) as the induction therapy. According to the current NMA, azole_H did not achieve a significantly cumulative hepatic toxicity effect. Moreover, AmphB plus fluconazole (800 mg/day) could be adopted as the standard induction antifungal regimen after Cryptococcal Optimal ART Timing Trial for HIV–CM patients.

Discussion
Our NMA summarizes the current evidence on the efficacy and tolerability of the induction therapy for individual antifungals in HIV–CM patients. And our results showed that AmphB + 5-FC + Azole as induction regimen yielded a lower mortality rate than other antifungal regimens. All the investigated antifungals were associated with a similar early mortality rate and also with a similar late mortality rate in HIV–CM patients. Based on mycological suppression, the azole_H alone was not recommended to be induction regimen in HIV–CM patients due to poor fungicidal activity. In summary, AmphB + 5-FC + Azole are superior to all investigated regimens for induction and the azole_H alone was not recommended to be induction regimen in HIV–CM patients due to poor fungicidal activity in HIV–CM patients.

Our NMA also found that the AmphB + 5-FC + Azole are superior to all the investigated treatments for induction regimens in HIV–CM patients. In contrast to Tenforde et al., our study did not found that 1-week AmphB + 5-FC-based therapy was superior to other regimens used to treat HIV–CM. As shown in a previous meta-analysis, the combination of AmphB + 5-FC + azole showed mostly significantly lower early mortality rate (Fig. 1), but, the result came from only a single study. The evidence is not conclusive due to the small sample bias. In addition, there was no statistically significant difference in mortality rates and hepatic adverse events between AmphB + azole_H and AmphB + 5-FC for HIV–CM patients. Briefly, our study shows 1-week AmphB + 5-FC remains the best preferred regimen than others in HIV–CM patients.

The goal of treating CM is to attain cryptococcal eradication and to protect from neurological damage. Mycological suppression could achieve fungal eradication in CSF as a prognostic factor. In previous studies, mycological suppression was independently associated with mortality. Our result is similar to a previous report showing no statistically significant difference in MS between the investigated antifungals. Our current NMA revealed that all the investigated antifungals were associated with a similar mycological suppression compared to AmphB + 5-FC in participants with mycological suppression, but the azole_H alone presented with poorly fungicidal activity (OR = 3.8, 95% CIs = 0.62–23). The results of our analysis is in line with those of a previous report that the azole_H alone was not recommended to be an induction regimen in HIV–CM patients due to poor fungicidal activity. Due to disconnection of network from the reporting of mycological suppression events, the secondary outcome needs further evaluation to elucidate this viewpoint.

Anti-fungal agents have high toxicity and cause hepatotoxicity, although the effectiveness of AmphB for HIV–CM patients is outstanding. The administration of azole with AmphB is recommended for the induction treatment of CM. The most frequent hepatic adverse events were due to an increased hepatic injury related to azole. Guidelines issued in 2010 recommended AmphB plus fluconazole (800 mg/day) as the induction therapy. According to the current NMA, azole_H did not achieve a significantly cumulative hepatic toxicity effect. Moreover, AmphB plus fluconazole (800 mg/day) could be adopted as the standard induction antifungal regimen after Cryptococcal Optimal ART Timing Trial for HIV–CM patients.

Limitations
There are several limitations to be acknowledged in the current NMA. First, some data analyzed in this study were limited by under-powered statistics, namely in heterogeneity between and within studies and a small number of trials for some treatment arms. Second, in the current NMA, we did not exclude trials with small case numbers in both the intervention and control arms because most RCTs had zero of relapse cases; this yielded a relatively large confidence (or credible) intervals for some treatment comparisons, although we also adopted the Bayesian model to obtain more robust estimates. Lastly, in spite of comparing different antifungals in our NMA, future large RCTs are required to evaluate the effectiveness and safety of different induction regimens to determine the best regimen for the management of HIV–CM patients.

Conclusions
Our NMA provides synthesized current evidence on the efficacy and safety of individual antifungals in patients with HIV–CM for early mortality. We found that AmphB + 5-FC + Azole are superior to all the investigated treatments as induction regimens for HIV–CM. Our NMA contributes compelling evidence the impactful evidence with AmphB + 5-FC + Azole for treating HIV–CM to alleviate the burden of CM. Furthermore, azole_H alone is not recommended as an induction regimen for HIV–CM owing to its poor fungicidal activity. However, given the small number of studies included in the current analysis, future large-scale RCTs focusing on the efficacy of different dosages and treatment durations of antifungals in patients with HIV–CM should be conducted to support or refute the results of the current NMA.

Received: 4 December 2020; Accepted: 1 April 2021
Published online: 21 April 2021
References

1. Jarvis, J. N. et al. High ongoing burden of cryptococcal disease in Africa despite antiretroviral roll out. AIDS 23, 1182–1183. https://doi.org/10.1097/QAD.0b013e32832b0efc (2009).

2. Okongo, M., Morgan, D., Mayanja, B., Ross, A. & Whitworth, J. Causes of death in a rural, population-based human immunodeficiency virus type 1 (HIV-1) natural history cohort in Uganda. Int. J. Epidemiol. 27, 698–702. https://doi.org/10.1093/ije/27.4.698 (1998).

3. Jarvis, J. N. et al. Adult meningoencephalitis in a setting of high HIV and TB prevalence: findings from 4961 suspected cases. BMC Infect. Dis. 10, 67. https://doi.org/10.1186/1471-2334-10-67 (2010).

4. Tenforde, M. W. et al. Mortality from HIV-associated meningoencephalitis in sub-Saharan Africa: a systematic review and meta-analysis. J. Int. AIDS Soc. https://doi.org/10.1002/jia2.25416 (2020).

5. Perfect, J. R. et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 50, 291–322. https://doi.org/10.1086/649858 (2010).

6. World Health Organization. Guidelines for the diagnosis, prevention, and management of cryptococcal disease in HIV-infected adults, adolescents and children, March 2018: supplement to the 2016 consolidated guidelines of the use of antiretroviral drugs for treating and preventing HIV infection. (2018).

7. Rhein, J. et al. Detrimental outcomes of unmasking cryptococcal meningoencephalitis with recent ART initiation. Open Forum Infect. Dis. 5, ofy122. https://doi.org/10.1093/ofid/ofy122 (2018).

8. Boyer-Chammard, T. et al. Recent advances in managing HIV-associated cryptococcal meningoencephalitis. F1000Res https://doi.org/10.12688/f1000research.17673.1 (2019).

9. Govender, N. et al. Guideline for the prevention, diagnosis and management of cryptococcal meningoencephalitis among HIV-infected persons: 2013 update. S. Afr. J. HIV Med. 14, 76–86 (2013).

10. Saag, M. S. et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal mieningoencephalitis. The NAID Mycoses Study Group and the AIDS Clinical Trials Group. N. Engl. J. Med. 326, 83–89. https://doi.org/10.1056/NEJM199209303260202 (1992).

11. Tenforde, M. W. et al. Treatment for HIV-associated cryptococcal meningoencephalitis. Cochrane Database Syst. Rev. 7, CD005647. https://doi.org/10.1002/14651858.CD005647.pub3 (2018).

12. Li, Y. et al. What is the most appropriate induction regimen for the treatment of HIV-associated cryptococcal meningoencephalitis when the recommended regimen is not available? Evidence from a network meta-analysis. Front. Pharmacol. 11, 963. https://doi.org/10.3389/fphar.2020.00963 (2020).

13. Jarvis, J. N. et al. Short-course high-dose liposomal amphotericin B for human immunodeficiency virus-associated cryptococcal meningitis: a phase 2 randomized controlled trial. Clin. Infect. Dis. 68, 393–401. https://doi.org/10.1093/cid/ciy515 (2019).

14. Loyse, A. et al. Comparison of the early fungicidal activity of high-dose fluconazole, voriconazole, and flucytosine as second-line drugs given in combination with amphotericin B for the treatment of HIV-associated cryptococcal meningitis. Clin. Infect. Dis. 54, 121–128. https://doi.org/10.1093/cid/cir745 (2012).

15. Yao, Z.-W., Lu, X., Shen, C. & Lin, D.-F. Comparison of flucytosine and fluconazole combined with amphotericin B for the treatment of HIV-associated cryptococcal meningitis: a systematic review and meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis. 33, 1339–1344 (2014).

16. Moher, D., Liberati, A., Tetzlaff, J. & Altman, D. G. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 6, e100097. https://doi.org/10.1371/journal.pmed.1000970 (2009).

17. Bicanic, T. et al. Independent association between rate of clearance of infection and clinical outcome of HIV-associated cryptococcal meningitis: analysis of a combined cohort of 262 patients. Clin. Infect. Dis. 49, 702–709. https://doi.org/10.1086/604716 (2009).

18. Higgins, J. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration. www.cochrane-handbook.org (2011).

19. Puhani, M. A. et al. GRADE Working Group approach for rating the quality of treatment effect estimates from network meta-analysis. BMJ 349, g5630. https://doi.org/10.1136/bmj.g5630 (2014).

20. White, I. R. Network meta-analysis. Stata J. 15, 951–985 (2015).

21. Chaimani, A. et al. Graphical tools for network meta-analysis in STATA. PLoS ONE 8, e76654. https://doi.org/10.1371/journal.pone.0076654 (2013).

22. Tu, Y. K. & Wu, W. C. Using structural equation modeling for network meta-analysis. BMC Med. Res. Methodol. 17, 104. https://doi.org/10.1186/s12874-017-0390-9 (2017).

23. Song, F. et al. Inconsistency between direct and indirect comparisons of competing interventions: meta-epidemiological study. BMJ 343, d4909. https://doi.org/10.1136/bmj.d4909 (2011).

24. Chotomongkol, V., Sukkaewsrisarnsawat, W. & Thavornpitak, Y. Comparison of amphotericin B, fluconazole and itraconazole with amphotericin B and fluconazole in the treatment of cryptococcal meningitis in AIDS. J. Med. Assoc. Thail. 80, 416–425 (1997).

25. Saag, M. S. et al. Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. Clin. Infect. Dis. 30, 710–718. https://doi.org/10.1086/313757 (2000).

26. Temfack, E. et al. Cryptococcal antigen in serum and cerebrospinal fluid for detecting cryptococcal meningitis in adults with HIV: systematic review and meta-analysis of diagnostic test accuracy studies. Clin. Infect. Dis. https://doi.org/10.1093/cid/ciaa1243 (2020).

27. Nussbaum, J. C. et al. Combination fluconazole and high-dose fluconazole compared with fluconazole monotherapy for the treatment of cryptococcal meningitis: a randomized trial in Malawi. Clin. Infect. Dis. 50, 338–344. https://doi.org/10.1097/QAD.0b013e32832b8e61 (2010).

28. Loyse, A., Dromer, F., Day, J., Lortholary, O. & Harrison, T. S. Fluconazole and cryptococcosis: time to urgently address the worldwide accessibility of a 50-year-old antifungal. J. Antimicrob. Chemother. 68, 2435–2444. https://doi.org/10.1093/jac/dkx221 (2013).

29. Stott, K. E. et al. Population pharmacokinetics and cerebrospinal fluid penetration of fluconazole in adults with cryptococcal meningitis. Antimicrob. Agents Chemother. https://doi.org/10.1128/AAC.00885-18 (2018).

30. Gullo, F. P. et al. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment. Eur. J. Clin. Microbiol. Infect. Dis. 32, 1377–1391. https://doi.org/10.1007/s10096-013-1915-8 (2013).

31. Bicanic, T., Ogden, D., Whitney, L., Loyse, A. & Jarvis, J. British HIV Association opportunistic infection guidelines: in defence of amphotericin B deoxycholate. HIV Med. 13, 636–637. https://doi.org/10.1111/j.1468-1292.2012.01022.x (2012).

32. Brizendine, K. D. & Pappas, P. G. Cryptococcal meningitis: current approaches to management in patients with and without AIDS. Curr. Infect. Dis. Rep. 12, 299–305. https://doi.org/10.1007/s11908-010-0113-4 (2010).

33. Brockhaus, A. C., Bender, R. & Skipka, G. The Peto odds ratio viewed as a new effect measure. Stat. Med. 33, 4861–4874. https://doi.org/10.1002/sim.6301 (2014).

34. Cheng, J., Pullenayegum, E., Marshall, J. K., Iorio, A. & Thabane, L. Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study. BMJ Open 6, e010983. https://doi.org/10.1136/bmjopen-2015-010983 (2016).
Acknowledgements
This research project would not have been possible without the support of many people. The authors wish to express their gratitude to the staffs of the Department of Neurosurgery, Division of Critical Care Medicine, the Division of Infectious Diseases, the Department of Pharmacology, the Department of Computer Science and the Department of Healthcare Quality at Changhua Christian Hospital who were extremely helpful and provided invaluable assistance and support.

Author contributions
Y.K.T. is acting as the guarantor of this article. C.H.C., H.L., H.M.C., Y.M.C., Y.J.C., K.H.L. and Y.K.T. helped to design and refine the systematic search strategy. C.H.C., H.L., H.M.C., Y.M.C., Y.J.C. and K.H.L. screened selected studies for inclusion and extracted relevant data. C.H.C., H.L., H.M.C., Y.M.C., Y.J.C., P.Y.L., C.W.H., P.T.T. and Y.K.T. were involved in the analysis of the data. All authors were involved in the interpretation of data and results. C.H.C., H.L., P.Y.L., C.W.H., P.T.T., and Y.K.T. contributed to the first draft of the manuscript. All authors contributed to the revision and refinement of the final manuscript. All authors had full access to all study data, have given final approval of this version of the manuscript to be published, and agree to be accountable to all aspects of the work. All authors read and approved the final manuscript.

Funding
The present work was partially supported by a grant obtained from the Changhua Christian Hospital (108-CCH-IRP-008 and 109-CCH-IRP-004).

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-87726-6.

Correspondence and requests for materials should be addressed to Y.-K.T.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2021